ALEC - Alector, Inc.

2
-0.120   -6.000%

Share volume: 466,450
Last Updated: 03-27-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$2.12
-0.12
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 39%
Liquidity 47%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.91%
1 Month
-9.50%
3 Months
31.58%
6 Months
-34.43%
1 Year
55.04%
2 Year
-66.78%
Key data
Stock price
$2.00
P/E Ratio 
0.00
DAY RANGE
$1.98 - $2.15
EPS 
-$1.39
52 WEEK RANGE
$0.87 - $3.40
52 WEEK CHANGE
$62.60
MARKET CAP 
170.276 M
YIELD 
N/A
SHARES OUTSTANDING 
110.363 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
2.04
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$663,782
AVERAGE 30 VOLUME 
$856,945
Company detail
CEO: Arnon Rosenthal
Region: US
Website: alector.com
Employees: 270
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the. treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases.

Recent news